OBJECTIVE: Suppression of ovarian hormones in premenopausal women ongonadotropin-releasing hormone agonist (GnRH(AG)) therapy can cause fat mass (FM) gain and fat-free mass (FFM) loss. Whether this is specifically caused by a decline in serum estradiol (E2) is unknown. This study aims to evaluate the effects of GnRH(AG) with placebo (PL) or E2 add-back therapy on FM, FFM, and bone mineral density (BMD). Our exploratory aim was to evaluate the effects of resistance exercise training on body composition during the drug intervention. METHODS:Seventy healthy premenopausal women underwent 5 months of GnRH(AG) therapy and were randomized to receive transdermal E2 (GnRH(AG) + E2, n = 35) or PL (GnRH(AG) + PL, n = 35) add-back therapy. As part of our exploratory aim to evaluate whether exercise can minimize the effects of hormone suppression, some women within each drug arm were randomized to undergo a resistance exercise program (GnRH(AG) + E2 + Ex, n = 12; GnRH(AG) + PL + Ex, n = 12). RESULTS: The groups did not differ in mean (SD) age (36 [8] and 35 [9] y) or mean (SD) body mass index (both 28 [6] kg/m). FFM declined in response to GnRH(AG) + PL (mean, -0.6 kg; 95% CI, -1.0 to -0.3) but not in response to GnRH(AG) + E2 (mean, 0.3 kg; 95% CI, -0.2 to 0.8) or GnRH(AG) + PL + Ex (mean, 0.1 kg; 95% CI, -0.6 to 0.7). Although FM did not change in either group, visceral fat area increased in response to GnRH(AG) + PL but not in response to GnRH(AG) + E2. GnRH(AG) + PL induced a decrease in BMD at the lumbar spine and proximal femur that was prevented by E2. Preliminary data suggest that exercise may have favorable effects on FM, FFM, and hip BMD. CONCLUSIONS: Suppression of ovarian E2 results in loss of bone and FFM and expansion of abdominal adipose depots. Failure of hormone suppression to increase total FM conflicts with previous studies of the effects of GnRH(AG). Further research is necessary to understand the role of estrogen in energy balance regulation and fat distribution.
RCT Entities:
OBJECTIVE: Suppression of ovarian hormones in premenopausal women on gonadotropin-releasing hormone agonist (GnRH(AG)) therapy can cause fat mass (FM) gain and fat-free mass (FFM) loss. Whether this is specifically caused by a decline in serum estradiol (E2) is unknown. This study aims to evaluate the effects of GnRH(AG) with placebo (PL) or E2 add-back therapy on FM, FFM, and bone mineral density (BMD). Our exploratory aim was to evaluate the effects of resistance exercise training on body composition during the drug intervention. METHODS: Seventy healthy premenopausal women underwent 5 months of GnRH(AG) therapy and were randomized to receive transdermal E2 (GnRH(AG) + E2, n = 35) or PL (GnRH(AG) + PL, n = 35) add-back therapy. As part of our exploratory aim to evaluate whether exercise can minimize the effects of hormone suppression, some women within each drug arm were randomized to undergo a resistance exercise program (GnRH(AG) + E2 + Ex, n = 12; GnRH(AG) + PL + Ex, n = 12). RESULTS: The groups did not differ in mean (SD) age (36 [8] and 35 [9] y) or mean (SD) body mass index (both 28 [6] kg/m). FFM declined in response to GnRH(AG) + PL (mean, -0.6 kg; 95% CI, -1.0 to -0.3) but not in response to GnRH(AG) + E2 (mean, 0.3 kg; 95% CI, -0.2 to 0.8) or GnRH(AG) + PL + Ex (mean, 0.1 kg; 95% CI, -0.6 to 0.7). Although FM did not change in either group, visceral fat area increased in response to GnRH(AG) + PL but not in response to GnRH(AG) + E2. GnRH(AG) + PL induced a decrease in BMD at the lumbar spine and proximal femur that was prevented by E2. Preliminary data suggest that exercise may have favorable effects on FM, FFM, and hip BMD. CONCLUSIONS: Suppression of ovarian E2 results in loss of bone and FFM and expansion of abdominal adipose depots. Failure of hormone suppression to increase total FM conflicts with previous studies of the effects of GnRH(AG). Further research is necessary to understand the role of estrogen in energy balance regulation and fat distribution.
Authors: R J Walker; N J Lewis-Barned; W H Sutherland; A Goulding; E A Edwards; S A de Jong; E Gold; H L Walker Journal: Menopause Date: 2001 Jan-Feb Impact factor: 2.953
Authors: Joel S Finkelstein; Hang Lee; Sherri-Ann M Burnett-Bowie; J Carl Pallais; Elaine W Yu; Lawrence F Borges; Brent F Jones; Christopher V Barry; Kendra E Wulczyn; Bijoy J Thomas; Benjamin Z Leder Journal: N Engl J Med Date: 2013-09-12 Impact factor: 91.245
Authors: Edward L Melanson; Kathleen M Gavin; Karen L Shea; Pamela Wolfe; Margaret E Wierman; Robert S Schwartz; Wendy M Kohrt Journal: J Appl Physiol (1985) Date: 2015-09-03
Authors: Kara L Marlatt; Leanne M Redman; Robbie A Beyl; Steve R Smith; Catherine M Champagne; Fanchao Yi; Jennifer C Lovejoy Journal: Am J Obstet Gynecol Date: 2019-10-11 Impact factor: 8.661
Authors: Gail A Greendale; Barbara Sternfeld; MeiHua Huang; Weijuan Han; Carrie Karvonen-Gutierrez; Kristine Ruppert; Jane A Cauley; Joel S Finkelstein; Sheng-Fang Jiang; Arun S Karlamangla Journal: JCI Insight Date: 2019-03-07
Authors: Justin C Brown; Bette J Caan; Carla M Prado; Elizabeth M Cespedes Feliciano; Jingjie Xiao; Candyce H Kroenke; Jeffrey A Meyerhardt Journal: J Natl Cancer Inst Date: 2020-04-01 Impact factor: 13.506
Authors: Edward L Melanson; Kate Lyden; Ellie Gibbons; Kathleen M Gavin; Pamela Wolfe; Margaret E Wierman; Robert S Schwartz; Wendy M Kohrt Journal: Med Sci Sports Exerc Date: 2018-08 Impact factor: 5.411
Authors: Kathleen M Gavin; Edward L Melanson; Kerry L Hildreth; Ellie Gibbons; Daniel H Bessesen; Wendy M Kohrt Journal: Obesity (Silver Spring) Date: 2020-11 Impact factor: 5.002
Authors: Kathleen M Gavin; Karen L Shea; Ellie Gibbons; Pamela Wolfe; Robert S Schwartz; Margaret E Wierman; Wendy M Kohrt Journal: Am J Physiol Endocrinol Metab Date: 2018-04-06 Impact factor: 4.310